Down syndrome, accelerated aging and immunosenescence.

Semin Immunopathol

Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, 40138, Bologna, Italy.

Published: October 2020

Down syndrome is the most common chromosomal disorder, associated with moderate to severe intellectual disability. While life expectancy of Down syndrome population has greatly increased over the last decades, mortality rates are still high and subjects are facing prematurely a phenomenon of atypical and accelerated aging. The presence of an immune impairment in Down syndrome subjects is suggested for a long time by the existence of an increased incidence of infections, the incomplete efficacy of vaccinations, and a high prevalence of autoimmunity. Immunologic abnormalities have been described since many years in this population, both from a numerical and a functional points of view, and these abnormalities can mirror the ones observed during normal aging. In this review, we summarize our knowledge on immunologic disturbances commonly observed in subjects with Down syndrome, and in innate and adaptive immunity, as well as regarding chronic inflammation. We then discuss the role of accelerated aging in these observed abnormalities and finally review the potential age-associated molecular and cellular mechanisms involved.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666319PMC
http://dx.doi.org/10.1007/s00281-020-00804-1DOI Listing

Publication Analysis

Top Keywords

accelerated aging
12
syndrome
5
syndrome accelerated
4
aging
4
aging immunosenescence
4
immunosenescence syndrome
4
syndrome common
4
common chromosomal
4
chromosomal disorder
4
disorder associated
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, NSW, Australia.

Background: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the impairment of cognitive development and disruption of neurocognitive function. This neuropathological condition is marked by neurodegeneration, loss of neural tissue, and the formation of neurofibrillary tangles and Aβ plaques. Various studies reported the utilization of phytoconstituents like fisetin, quercetin, berberine, and xanthohumol for the treatment of AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Background: Our limited understanding of the mechanisms that trigger the emergence of Alzheimer's disease (AD) has contributed to the lack of interventions that stop, prevent, or fully treat this disease. We believe that developing a nonhuman primate model of AD will be an essential step toward overcoming the limitations of other model systems and is crucial for investigating primate-specific mechanisms underlying the cellular and molecular root causes of the pathogenesis and progression of AD.

Method: The consortium successfully generated viable founders carrying PSEN1 mutations.

View Article and Find Full Text PDF

Background: Cognitive impairment, a common aging-related pathology, is a risk factor for dementia. Echinacoside (ECH), derived from the traditional Chinese medicine Cistanche deserticola, shows anti-aging properties including anti-inflammation, oxidative stress reduction, and neuronal protection. Despite its benefits, the beneficial impact of ECH on age-related cognitive decline remains unclear.

View Article and Find Full Text PDF

Background: Dementia, a growing health crisis, disproportionally affects persons from racial/ethnic backgrounds and individuals with comorbidities. Latelife change in cognition is complex and nonlinear, as well as differential for these individuals. These individuals are also largely underrepresented in clinical trials.

View Article and Find Full Text PDF

Background: The Collaborative Approach for Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPI) Research and Education (CARE) is a recruitment registry that has enrolled over 10,000 AANHPI participants who expressed willingness to participate in Alzheimer's disease and related dementias (ADRD), aging, caregiving, and other health research. We report survey results from 24 of the 28 study principal investigators ("users") who utilized CARE between January 2021 and October 2023 to support their study recruitment.

Method: Users answered five questions on a 4-point Likert scale (0 = Strongly disagree to 3 = Strongly agree) related to (1) user experience, (2) usefulness in accelerating recruitment, (3) improving AANHPI representation, (4) whether they would use the registry again, and (5) whether they would recommend the registry to others.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!